![]()
finasteride
The baldness drug propecia could help reduce the risk of prostate cancer with less side-effects than previously thought, according to a new study.

Warding off prostate cancer may be as easy as growing your hair, according to new data published in the New England Journal of Medicine by researchers from the University of Texas Health Science Center at San Antonio. The researchers followed up on patients from one of their previous studies, and found that the baldness drug finasteride, also known as Propecia, reduced the risk of prostate cancer by more than a third, and resulted in less-severe side effects than previously thought.
“If you look at the number of prostate cancers that are diagnosed annually and multiply that by 30 percent, that’s the number of cancers we might be able to prevent each year,” Ian Thompson Jr., MD, study author and director of the Cancer Therapy & Research Center at the University of Texas, said in a statement. “That’s more than 71,000 men. That’s more than 175 jumbo jets full of men who won’t get cancer, who won’t face treatments with side effects like sexual dysfunction.”
read all at
Finasteride (brand names Proscar and Propecia by Merck, among other generic names) is a synthetic drug for the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB). It is a type II 5α-reductase inhibitor. 5α-reductase is an enzymethat converts testosterone to dihydrotestosterone (DHT).
Finasteride is synthesized fromprogesterone:
- Rasmusson GH, Reynolds GF, Steinberg NG, Walton E, Patel GF, Liang T, Cascieri MA, Cheung AH, Brooks JR, Berman C (November 1986). “Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding”. J. Med. Chem.29 (11): 2298–315. doi:10.1021/jm00161a028. PMID 3783591.
- ^ Bhattacharya A, Dimichele LM, Dolling U, Douglas AW, Grabowski EJJ (1988). “Silylation-mediated oxidation of 4-aza-3-ketosteroids with DDQ proceeds via DDQ-substrate adducts”. Journal of the American Chemical Society 110: 3318–9. doi:10.1021/ja00218a062.
![]()
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

Reblogged this on MedCheminSingapore by Sushma Wang.
LikeLike
Reblogged this on MED.CHEM in BURMA.
LikeLike
Reblogged this on MedChemHot.Pakistan.
LikeLike
Reblogged this on MEDCHEMEGYPT.
LikeLike
Reblogged this on MariaGairos–DRUGS.
LikeLike
Reblogged this on MedCheminAustralia.
LikeLike
Reblogged this on My Blog on Medicinal Chemistry.
LikeLike
Reblogged this on Vijaya Shastry Ph.D Physical Chemistry.
LikeLike
Reblogged this on Med.Chem.in.Iceland.
LikeLike